Deals
The OIS Index of ophthalmic stocks staged a strong comeback in Q2, gaining 21.4%, in line with the overall US stock market as measured by…
Read MoreMost transformations are predictable: A caterpillar will turn into a butterfly; a cell will be genetically altered should extraneous DNA enter its membrane. Predictable would…
Read MoreNow that it has closed on its $63 billion acquisition of Allergan, AbbVie has significantly expanded its revenue base, which could help cushion the blow…
Read MoreThe turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that…
Read MoreThe OIS Index of ophthalmic stocks followed global stock markets into bear market territory in Q1, declining 21.2%, in line with the overall US stock…
Read MoreThe explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where…
Read MoreLast week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the…
Read MoreEditor’s Note: The FDA just approved Allergan’s Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on…
Read MoreAs reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…
Read MoreIsrael’s second name is “start-up nation,” and there are anywhere from 50-70 companies developing products for the eye care industry in Israel. From a monetary…
Read MoreMedia coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a…
Read MoreThe OIS Index of ophthalmic stocks made a strong comeback in Q4-2019, following a rough Q3. The index gained 16.2% in Q4, slightly underperforming the…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.